Table 2.

Table 2A: Baseline characteristics of patients included within the two periods
Characteristics	Cotrimoxazole alone period*	HAART plus cotrimoxazole period*
Number of patients	446	135
Baseline age, median (IQR)	32 (27–38)	35 (29–41)
Sex, female (%)	265 (59%)	85 (63%)
Baseline CD4 count/μl, median (IQR)	248 (138–446)	127 (58–226)
Baseline WHO stage, n (%)
Stage 3	244 (55%)	61 (45%)
Stage 4	69 (15%)	56 (41%)

Table 2B: Follow-up characteristics of patients included within the two periods
Characteristics	Cotrimoxazole alone period*	HAART plus cotrimoxazole period*
Follow-up time on treatment
Cumulative, person-months
Overall	6,216	3,412
By CD4 stratum
Within CD4 ≤ 50/μl	615	102
Within CD4 51–200/μl	1,883	1,129
Within CD4 >200/μl	3,714	2,184
Median (IQR), months	10.1 (8.8–20.0)	25.5 (15.2–37.0)
Number of events during follow-up
Death, number of events
Overall	97	15
By CD4 stratum
Within CD4 ≤ 50/μl	33	6
Within CD4 51–200/μl	42	8
Within CD4 >200/μl	22	1
By time since HAART initiation
0–6 months		8
> 6 months		7
Severe morbidity, number of events
Overall	217	73
By CD4 stratum
Within CD4 ≤ 50/μl	41	8
Within CD4 51–200/μl	84	25
Within CD4 >200/μl	92	40
By time since HAART initiation
0–6 months		37
> 6 months		36
CD4 measurements during follow-up
Number of measurements per patient, median (IQR), range	2 (2–3), range: 1–7	8 (4–14), range: 1–23
Number of measurements ≤ 50/μl; median (IQR)	115; 17 (5–33)	71; 15 (7–29)
Number of measurements 51–200/μl; median (IQR)	355; 133 (90–168)	423; 138 (98–171)
Number of measurements >200/μl; median (IQR)	679; 390 (272–603)	768; 336 (262–477)

HAART: Highly active antiretroviral therapy; IQR: Interquartile range.

^*97 patients contributed successively to both periods.